Tradipitant
Tradipitant is a prescription NK1 receptor blocker used to prevent vomiting caused by motion in adults.
🧬 Where this information comes from
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Tradipitant (Nereus) is a newer capsule, on the U.S. market since about 2026 and not available as a generic, taken once before travel to prevent motion-induced vomiting in adults by blocking NK1 receptors, the brain's substance P receptors involved in vomiting, not the histamine or acetylcholine targets of older motion sickness medicines. It appears generally well tolerated, and the side effects people notice most are sleepiness, headache and tiredness. The one thing to watch is drowsiness and dulled alertness, so skip driving or machinery if it leaves you foggy. Avoid it if you have any liver problems or severe kidney disease, as the label advises.
Clinical pearls
- Take it about an hour before travel on an empty stomach, an hour before or two hours after a full meal.
- Use no more than one dose in 24 hours, and safety beyond 90 total doses has not been studied.
- Strong CYP3A4 inhibitors (drugs that slow its breakdown, like certain antifungals) raise its levels, so mention it to every prescriber.
- Sleep aids, opioids, anxiety medicines and other sedating drugs add to its drowsiness, so avoid stacking them before driving.
Patient Information Guide A plain-language walkthrough of Tradipitant, written from its FDA label.
What Tradipitant Is Used For
▾
Tradipitant is approved for one use in the supplied product evidence.
- Nereus (oral capsule) is used to prevent vomiting induced by motion in adults.
How Tradipitant Works
▾
Tradipitant is a selective blocker of substance P/neurokinin 1 (NK1) receptors. These receptors are involved in the body's vomiting signals. Tradipitant crosses the blood-brain barrier and occupies NK1 receptors in the brain. It does not bind to serotonin, dopamine, histamine or cholinergic receptors. The exact way it works is not fully established.
Tradipitant Dosage
▾
Nereus is taken by mouth as a single dose about 60 minutes before an event expected to cause motion-induced vomiting.
- Take it on an empty stomach, at least 1 hour before or 2 hours after a full meal.
- No more than one dose in 24 hours.
- Your prescriber will use the lowest effective dose.
- Safety beyond 90 doses has not been established in clinical trials.
Dosing details from the FDA-approved label
From the Tradipitant prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Prevention of vomiting induced by motion in adults
- 85 mg or 170 mg as a single oral dose approximately 60 minutes before an event expected to cause vomiting induced by motion
- Use the lowest effective dose
- Maximum: A single dose of 85 mg or 170 mg in a 24-hour period
- Administer on an empty stomach, at least 1 hour prior to or 2 hours after a full meal; safety for more than 90 doses has not been established in clinical trials
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION The recommended dosage of NEREUS is 85 mg or 170 mg as a single oral dose approximately 60 minutes before an event expected to cause vomiting induced by motion. The safety of NEREUS for the prevention of vomiting induced by motion in adults for more than 90 doses has not been established in clinical trials. ( 2.1 ) The maximum dosage in a 24-hour period is a single dose of 85 mg or 170 mg. ( 2.1 ) Administer on an empty stomach, at least 1 hour prior to or 2 hours after a full meal. ( 2.1 ) 2.1 Recommended Dosage and Administration The recommended dosage of NEREUS is 85 mg or 170 mg as a single oral dose. Use the lowest effective dose. The safety of NEREUS for the prevention of vomiting induced by motion in adults for more than 90 doses has not been established in clinical trials [see Adverse Reactions (6.1) ] . Administer NEREUS orally approximately 60 minutes before an event expected to cause vomiting induced by motion. The maximum dosage in a 24-hour period is a single dose of 85 mg or 170 mg. Administer NEREUS on an empty stomach, at least 1 hour prior to or 2 hours after a full meal [see Clinical Pharmacology (12.3) ] .
Read the full Dosage and Administration section on DailyMed →
Tradipitant Side Effects
▾
The most common side effects in trials were:
Common side effects
- Sleepiness (somnolence)
- Headache
- Fatigue (tiredness)
When to get medical help
- Call your doctor if you feel very drowsy or mentally foggy, or are unsafe to drive or operate machinery.
- Call your doctor if side effects are troublesome or don't go away.
- If you are breastfeeding, tell your doctor if your baby seems unusually sleepy.
Drowsiness can affect your ability to drive or operate machinery, so speak with your doctor if it is a problem.
Tradipitant Warnings and Precautions
▾
The biggest precaution is impaired alertness. Nereus may affect the mental and physical abilities needed to drive or operate heavy machinery. Sleepiness was reported in 6% of people on the lower dose and 12% on the higher dose, versus 4% and 6% on placebo.
Other CNS-depressing drugs and strong CYP3A4 inhibitors may make this worse. Avoid activities that need complete mental alertness if you are affected.
Tradipitant Interactions
▾
A few drug types can change how Nereus affects you.
- Strong CYP3A4 inhibitors: can raise tradipitant levels and the risk of side effects.
- Other CNS-depressing drugs: may add to sleepiness and impaired alertness.
- Alcohol: slightly raised tradipitant levels in a study, not considered clinically relevant.
Interactions listed in the FDA-approved label
From the Tradipitant prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Strong CYP3A4 inhibitors: Tradipitant is a CYP3A4 substrate, and strong CYP3A4 inhibitors may increase tradipitant exposure, which may increase the risk of adverse reactions to NEREUS.
Read the label’s full interactions text
7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: May increase tradipitant exposure and the risk of adverse reactions. ( 7.1 ) 7.1 Effects of Other Drugs on NEREUS Strong CYP3A4 Inhibitors Tradipitant is a CYP3A4 substrate. Strong CYP3A4 inhibitors may increase tradipitant exposure, which may increase the risk of adverse reactions to NEREUS.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before Taking Tradipitant
▾
- No contraindications are listed.
- Avoid in mild, moderate or severe liver impairment, as it has not been studied.
- Avoid in severe kidney impairment. Mild to moderate kidney impairment uses the same recommended dosing.
- Pregnancy: human data are insufficient; animal studies showed no harm to development.
- Breastfeeding: watch the infant for sleepiness.
- Children: safety and effectiveness have not been established.
- Older adults: no overall differences seen, though greater sensitivity cannot be ruled out.
What Tradipitant Does in the Body
▾
Tradipitant binds NK1 receptors very tightly and blocks substance P signaling. In a PET imaging study, it occupied up to 93% of brain NK1 receptors after repeated doses. At the highest recommended single dose taken without food, it did not cause clinically significant QTc prolongation (a heart rhythm change).
How Your Body Processes Tradipitant
▾
Peak blood levels occur about 1.5 to 2 hours after a fasting dose. Food, especially a high-fat meal, greatly raises drug levels and delays the peak, which is why it is taken on an empty stomach. Its half-life is about 34 hours. It is extensively broken down by the liver, partly by CYP3A4, and is cleared mostly in feces (about 80%), with little in urine (about 7%).
How to Store Tradipitant
▾
Store NEREUS capsules at controlled room temperature, 25°C (77°F); excursions permitted to 15°C to 30°C (59° - 86°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Tradipitant: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Tradipitant — the kind of thing our pharmacy team would talk through with you at the counter.
What is Nereus for?
▾
When and how should I take it?
▾
Will it make me sleepy?
▾
Are there medicines I should watch out for?
▾
Can I take it if I have liver or kidney problems?
▾
Is it safe in pregnancy or while breastfeeding?
▾
Is Tradipitant available over the counter?
▾
When was Tradipitant first available?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More About Tradipitant on HelloPharmacist
Tradipitant Forms and Strengths (How It Comes)
Tradipitant is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Tradipitant inactive ingredients by manufacturer.
Capsule
How this form is used
- Nereus is used to prevent vomiting induced by motion in adults.
- Nereus is taken by mouth as a single dose about 60 minutes before an event expected to cause motion-induced vomiting.
- Nereus should be taken on an empty stomach, at least 1 hour before or 2 hours after a full meal.
- Only one Nereus dose is allowed in a 24-hour period.
Tradipitant on the U.S. Market: Products, Makers and Brands
How Tradipitant appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 1 Tradipitant product record with the FDA, mostly as capsule; the earliest marketing or approval year on record is 2025. Brand names on the directory include Nereus; the rest are generics.
Compare Tradipitant Products
A representative set of FDA-listed product records for Tradipitant — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 85 mg | Oral | Vanda Pharmaceuticals Inc. | NDA | View NDC → |
Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Tradipitant NDCs →
Tradipitant Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Tradipitant — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Tradipitant in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Tradipitant FDA Approval History
How Tradipitant went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Tradipitant Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Tradipitant recalls since July 2021.
✅No Tradipitant recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Oct 8, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2739506 1 dose form · 1 strength
-
Dose form (SCDF) Oral Capsule RxCUI 2739510In current FDA listingsClinical drug / strength (SCD) 85 MGRxCUI 2739511
Look up RxCUI 2739506 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Tradipitant Supply and Shortage Status
Whether Tradipitant is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Tradipitant Brand Names
Tradipitant is sold under one brand name in the FDA directory — Nereus. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who Makes Tradipitant: Manufacturers and Labelers
One company lists Tradipitant products with the FDA. By number of product records, the largest are Vanda Pharmaceuticals Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Tradipitant Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Vanda Pharmaceuticals Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →